US FDA rejects Qutenza in HIV-PN; NeurogesX slashes workforce by 57%
This article was originally published in Scrip
Executive Summary
The news of the US FDA's rejection of NeurogesX's Qutenza (capsaicin 8%) patch as a therapy to manage HIV-associated peripheral neuropathy (HIV-PN) not only affected the San Mateo, California-based firm's shares on 8 March – which fell 20%, or 13 cents, to close at 53 cents – but also the company's workforce, which is being slashed by 57%.